CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint.
CD38
immune checkpoint
lymphocyte subsets
oral squamous cell carcinoma
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
03
2021
accepted:
27
05
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
CD38 belongs to the ribosyl cyclase family and is expressed on various hematological cells and involved in immunosuppression and tumor promotion. Although targeting CD38 antibodies has been approved for treatment of multiple myeloma, the function of CD38 in solid tumor, oral squamous cell carcinoma (OSCC) This retrospective study included 92 OSCC samples and analyzed the spatial distribution of CD38 by immunohistochemistry (IHC). The values of diagnosis and prognosis of CD38 were evaluated. Additionally, 53 OSCC preoperative peripheral blood samples were used to be analyzed by flow cytometry. Tumor Immune Estimation Resource (TIMER) and cBioPortal databases were used to study CD38 level in various tumors and its correlation with tumor immune microenvironment in head and neck squamous cell carcinoma (HNSCC). CD38 ubiquitously presented in tumor cells (TCs), fibroblast-like cells (FLCs), and tumor-infiltrating lymphocytes (TILs). Patients with highly expressed CD38 in TCs (CD38 CD38 is a poor prognostic biomarker for OSCC patients and plays a vital role in governing immune microenvironment and circulating lymphocyte homeostasis. Co-expression between CD38 and immune checkpoint molecules provides new insight into immune checkpoint therapy.
Sections du résumé
BACKGROUND
BACKGROUND
CD38 belongs to the ribosyl cyclase family and is expressed on various hematological cells and involved in immunosuppression and tumor promotion. Although targeting CD38 antibodies has been approved for treatment of multiple myeloma, the function of CD38 in solid tumor, oral squamous cell carcinoma (OSCC)
METHODS
METHODS
This retrospective study included 92 OSCC samples and analyzed the spatial distribution of CD38 by immunohistochemistry (IHC). The values of diagnosis and prognosis of CD38 were evaluated. Additionally, 53 OSCC preoperative peripheral blood samples were used to be analyzed by flow cytometry. Tumor Immune Estimation Resource (TIMER) and cBioPortal databases were used to study CD38 level in various tumors and its correlation with tumor immune microenvironment in head and neck squamous cell carcinoma (HNSCC).
RESULTS
RESULTS
CD38 ubiquitously presented in tumor cells (TCs), fibroblast-like cells (FLCs), and tumor-infiltrating lymphocytes (TILs). Patients with highly expressed CD38 in TCs (CD38
CONCLUSION
CONCLUSIONS
CD38 is a poor prognostic biomarker for OSCC patients and plays a vital role in governing immune microenvironment and circulating lymphocyte homeostasis. Co-expression between CD38 and immune checkpoint molecules provides new insight into immune checkpoint therapy.
Identifiants
pubmed: 34211854
doi: 10.3389/fonc.2021.687430
pmc: PMC8239289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
687430Informations de copyright
Copyright © 2021 Ding, He, Fu, Zhu, Zhao, Song, Huang, Chen, Yang, Zhang, Hu, Ni and Ding.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Carcinog. 2017 Oct;56(10):2245-2257
pubmed: 28544069
Carcinogenesis. 2018 Feb 9;39(2):242-251
pubmed: 29228209
Lab Invest. 2020 Dec;100(12):1517-1531
pubmed: 32612286
Int J Oncol. 2019 Feb;54(2):585-599
pubmed: 30535454
Oncol Lett. 2020 Oct;20(4):12
pubmed: 32774485
JCI Insight. 2018 Mar 22;3(6):
pubmed: 29563330
Cancer Res. 2015 Sep 15;75(18):3902-11
pubmed: 26170397
Cytogenet Cell Genet. 1995;69(1-2):38-9
pubmed: 7835083
Ann Oncol. 2019 Jan 1;30(1):57-67
pubmed: 30462163
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32847986
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480
Hepatology. 2000 Jun;31(6):1251-6
pubmed: 10827150
Surg Oncol. 2020 Mar;32:99-107
pubmed: 31983439
J Immunother Cancer. 2014 Nov 18;2(1):38
pubmed: 25436113
Cancer Manag Res. 2019 Nov 11;11:9553-9562
pubmed: 31807078
Cytometry B Clin Cytom. 2013 Jul-Aug;84(4):207-17
pubmed: 23576305
Front Immunol. 2020 Nov 30;11:597959
pubmed: 33329591
Oncol Lett. 2020 Jul;20(1):724-732
pubmed: 32565998
Cells. 2019 Dec 24;9(1):
pubmed: 31878283
J Oral Pathol Med. 2020 Feb;49(2):126-136
pubmed: 31660637
Br J Haematol. 2008 Aug;142(4):595-605
pubmed: 18503580
Blood. 2002 Apr 1;99(7):2490-8
pubmed: 11895784
Trends Mol Med. 2008 May;14(5):210-8
pubmed: 18403265
Expert Rev Anticancer Ther. 2019 Feb;19(2):105-119
pubmed: 30582397
J Biol Chem. 2018 May 25;293(21):8151-8160
pubmed: 29632067
Hematology. 2005 Feb;10(1):39-46
pubmed: 16019444
Oral Oncol. 2012 Sep;48(9):775-9
pubmed: 22520054
Oncol Rep. 2014 Dec;32(6):2703-9
pubmed: 25310288
J Immunol. 1989 Nov 15;143(10):3183-91
pubmed: 2530273
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Cells. 2020 Mar 21;9(3):
pubmed: 32245149
Blood. 2011 Sep 29;118(13):3470-8
pubmed: 21765022
Cells. 2020 Mar 26;9(4):
pubmed: 32225002